Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC

Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, tar...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	ZHU Kuikui, WU Gang
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	non-small cell lung cancer radiotherapy immune checkpoint inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/285b3c127ca447da9782f43b0837486a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:285b3c127ca447da9782f43b0837486a
record_format	dspace
spelling	oai:doaj.org-article:285b3c127ca447da9782f43b0837486a2021-11-05T02:22:52ZClinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC1000-857810.3971/j.issn.1000-8578.2021.21.0382https://doaj.org/article/285b3c127ca447da9782f43b0837486a2021-10-01T00:00:00Zhttp://html.rhhz.net/ZLFZYJ/html/8578.2021.21.0382.htmhttps://doaj.org/toc/1000-8578Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, targeted therapy and immune checkpoint inhibitors. As one of the traditional treatment methods, radiotherapy plays an important role in the treatment of all stages of NSCLC, and its immunomodulatory effect has attracted much attention. The application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with local-advanced and advanced NSCLC, but the benefit population was limited. At present, the treatment mode of radiotherapy combined with ICIs has become the focus of research. This paper reviews the research progress of radiotherapy combined with ICIs in the treatment of NSCLC.ZHU KuikuiWU GangMagazine House of Cancer Research on Prevention and Treatmentarticlenon-small cell lung cancerradiotherapyimmune checkpoint inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 10, Pp 916-921 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	non-small cell lung cancer radiotherapy immune checkpoint inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	non-small cell lung cancer radiotherapy immune checkpoint inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 ZHU Kuikui WU Gang Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
description	Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, targeted therapy and immune checkpoint inhibitors. As one of the traditional treatment methods, radiotherapy plays an important role in the treatment of all stages of NSCLC, and its immunomodulatory effect has attracted much attention. The application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with local-advanced and advanced NSCLC, but the benefit population was limited. At present, the treatment mode of radiotherapy combined with ICIs has become the focus of research. This paper reviews the research progress of radiotherapy combined with ICIs in the treatment of NSCLC.
format	article
author	ZHU Kuikui WU Gang
author_facet	ZHU Kuikui WU Gang
author_sort	ZHU Kuikui
title	Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
title_short	Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
title_full	Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
title_fullStr	Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
title_full_unstemmed	Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
title_sort	clinical research progress of radiotherapy combined with immune checkpoint inhibitors on nsclc
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/285b3c127ca447da9782f43b0837486a
work_keys_str_mv	AT zhukuikui clinicalresearchprogressofradiotherapycombinedwithimmunecheckpointinhibitorsonnsclc AT wugang clinicalresearchprogressofradiotherapycombinedwithimmunecheckpointinhibitorsonnsclc
_version_	1718444518000295936

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC

Ejemplares similares